Mikael Chéramy

Summary

Country: Sweden

Publications

  1. doi request reprint GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response
    Mikael Chéramy
    Division of Paediatrics and Diabetes Research Centre, Department of Clinical and Experimental Medicine, Linkoping University, Sweden
    Clin Immunol 137:31-40. 2010
  2. pmc Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial
    Stina Axelsson
    Corresponding author Mikael Chéramy
    Diabetes Care 36:3418-24. 2013
  3. pmc Characteristics of in-vitro phenotypes of glutamic acid decarboxylase 65 autoantibodies in high-titre individuals
    M Chéramy
    Division of Pediatrics, Department of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden
    Clin Exp Immunol 171:247-54. 2013
  4. pmc Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes
    Stina Axelsson
    Division of Paediatrics, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    PLoS ONE 6:e29008. 2011
  5. pmc GAD autoantibody epitope pattern after GAD-alum treatment in children and adolescents with type 1 diabetes
    Camilla Skoglund
    Division of Pediatrics and Diabetes Research Centre, Department of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden
    Pediatr Diabetes 13:244-50. 2012
  6. doi request reprint GAD treatment and insulin secretion in recent-onset type 1 diabetes
    Johnny Ludvigsson
    Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    N Engl J Med 359:1909-20. 2008
  7. ncbi request reprint GAD-treatment of children and adolescents with recent-onset type 1 diabetes preserves residual insulin secretion after 30 months
    Johnny Ludvigsson
    Department of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden Pediatric Clinic, County Council of Ostergotland, Linkoping, Sweden
    Diabetes Metab Res Rev 30:405-14. 2014
  8. doi request reprint Immune intervention in children with type 1 diabetes
    Johnny Ludvigsson
    Department of Clinical and Experimental Medicine, Division of Pediatrics, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    Curr Diab Rep 10:370-9. 2010

Detail Information

Publications8

  1. doi request reprint GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response
    Mikael Chéramy
    Division of Paediatrics and Diabetes Research Centre, Department of Clinical and Experimental Medicine, Linkoping University, Sweden
    Clin Immunol 137:31-40. 2010
    ..In the GAD-alum group, higher pre-treatment GADA were associated to more pronounced C-peptide preservation. The induced IgG3/IgG4 and reduced IgG1 suggest a Th2 deviation of the immune response...
  2. pmc Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial
    Stina Axelsson
    Corresponding author Mikael Chéramy
    Diabetes Care 36:3418-24. 2013
    ..The European phase III study was therefore closed after 15 months, and only a minority of patients completed the 30 months of follow-up...
  3. pmc Characteristics of in-vitro phenotypes of glutamic acid decarboxylase 65 autoantibodies in high-titre individuals
    M Chéramy
    Division of Pediatrics, Department of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden
    Clin Exp Immunol 171:247-54. 2013
    ..However, occasional overlap between the groups exists, and caution is indicated when drawing conclusions to health or disease status...
  4. pmc Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes
    Stina Axelsson
    Division of Paediatrics, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    PLoS ONE 6:e29008. 2011
    ..In parallel to a GAD(65)-induced T-cell activation, our results show induction of T-cell inhibitory pathways important for regulating the GAD(65) immunity...
  5. pmc GAD autoantibody epitope pattern after GAD-alum treatment in children and adolescents with type 1 diabetes
    Camilla Skoglund
    Division of Pediatrics and Diabetes Research Centre, Department of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden
    Pediatr Diabetes 13:244-50. 2012
    ..The aim of this study was to investigate whether GAD-alum treatment affected the GADA epitope pattern...
  6. doi request reprint GAD treatment and insulin secretion in recent-onset type 1 diabetes
    Johnny Ludvigsson
    Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    N Engl J Med 359:1909-20. 2008
    ..This trial assessed the ability of alum-formulated GAD (GAD-alum) to reverse recent-onset type 1 diabetes in patients 10 to 18 years of age...
  7. ncbi request reprint GAD-treatment of children and adolescents with recent-onset type 1 diabetes preserves residual insulin secretion after 30 months
    Johnny Ludvigsson
    Department of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden Pediatric Clinic, County Council of Ostergotland, Linkoping, Sweden
    Diabetes Metab Res Rev 30:405-14. 2014
    ....
  8. doi request reprint Immune intervention in children with type 1 diabetes
    Johnny Ludvigsson
    Department of Clinical and Experimental Medicine, Division of Pediatrics, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    Curr Diab Rep 10:370-9. 2010
    ..Combination of immune intervention, protection of the beta cells, and stimulation of regeneration may lead to a milder disease or even a cure in the future, and prevention is no longer unrealistic...